PubRank

R A Franklin

Author PubWeight™ 55.88‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy. Leukemia 2003 3.89
2 Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention. Leukemia 2003 2.89
3 JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis. Leukemia 2004 2.76
4 Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibitors. Oncogene 2008 1.73
5 Differential effects of kinase cascade inhibitors on neoplastic and cytokine-mediated cell proliferation. Leukemia 2003 1.56
6 Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy. Leukemia 2011 1.51
7 A review of the biological properties and metabolic disposition of the new analgesic agent, meptazinol. Gen Pharmacol 1978 1.47
8 The pharmacokinetics of ciclazindol (Wy 23409) in human volunteers. Br J Clin Pharmacol 1977 1.44
9 Rapamycin blocks cell cycle progression of activated T cells prior to events characteristic of the middle to late G1 phase of the cycle. J Cell Physiol 1993 1.25
10 Rapamycin inhibits the phosphorylation of p70 S6 kinase in IL-2 and mitogen-activated human T cells. Biochem Biophys Res Commun 1992 1.23
11 Failure of rapamycin to block proliferation once resting cells have entered the cell cycle despite inactivation of p70 S6 kinase. J Biol Chem 1993 1.19
12 Signal transduction, cell cycle regulatory, and anti-apoptotic pathways regulated by IL-3 in hematopoietic cells: possible sites for intervention with anti-neoplastic drugs. Leukemia 1999 1.09
13 Role of the Raf signal transduction cascade in the in vitro resistance to the anticancer drug doxorubicin. Clin Cancer Res 2001 1.06
14 Studies on the metabolism of meptazinol, a new analgesic drug. Br J Clin Pharmacol 1976 1.03
15 Pharmacokinetic studies on WY 23409 HCl. Br J Clin Pharmacol 1975 1.03
16 The classification of benzodiazepine hypnotics. Br J Clin Pharmacol 1983 1.00
17 A conditionally-active form of MEK1 results in autocrine tranformation of human and mouse hematopoietic cells. Oncogene 2000 0.98
18 Induction of IL-2 and lymphokine activated killer cells in the cat. Vet Immunol Immunopathol 1987 0.97
19 Preliminary metabolic studies on the new analgesic meptazinol. Br J Clin Pharmacol 1975 0.94
20 Interactions between the PI3K and Raf signaling pathways can result in the transformation of hematopoietic cells. Cancer Detect Prev 2001 0.92
21 Cross-linking of surface IgM stimulates the Ras/Raf-1/MEK/MAPK cascade in human B lymphocytes. J Biol Chem 1994 0.91
22 Differential abilities of the Raf family of protein kinases to abrogate cytokine dependency and prevent apoptosis in murine hematopoietic cells by a MEK1-dependent mechanism. Leukemia 2000 0.86
23 Requirement for the PI3K/Akt pathway in MEK1-mediated growth and prevention of apoptosis: identification of an Achilles heel in leukemia. Leukemia 2003 0.86
24 Differential abilities of activated Raf oncoproteins to abrogate cytokine dependency, prevent apoptosis and induce autocrine growth factor synthesis in human hematopoietic cells. Leukemia 1998 0.85
25 One hundred doctors at The Retreat. A contribution to the subject of mental disorder in the medical profession. Br J Psychiatry 1977 0.85
26 Nerve growth factor signal transduction in human B lymphocytes is mediated by gp140trk. Eur J Immunol 1996 0.85
27 Signal transduction by interleukin 2 in human T cells: activation of tyrosine and ribosomal S6 kinases and cell-cycle regulatory genes. J Cell Physiol 1992 0.83
28 Monoclonal antibodies directed to different epitopes in the CD3-TCR complex induce different states of competence in resting human T cells. J Immunol 1992 0.83
29 Pharmacokinetics of intravenous indoramin in middle-aged male and female volunteers. Eur J Clin Pharmacol 1983 0.82
30 Calcium-induced ERK activation in human T lymphocytes. Mol Immunol 1999 0.81
31 Pharmacokinetics of the new analgesic, meptazinol, after oral and intravenous administration to volunteers. Eur J Clin Pharmacol 1983 0.81
32 Preliminary studies on the disposition of meptazinol in the neonate. Br J Clin Pharmacol 1981 0.81
33 Human CD45RA+ and CD45R0+ T cells exhibit similar CD3/T cell receptor-mediated transmembrane signaling capacities but differ in response to co-stimulatory signals. Eur J Immunol 1994 0.80
34 Seroprevalence of herpes simplex virus type 2 antibodies in New Zealand sexual health clinic patients. N Z Med J 1996 0.80
35 The disposition of a novel pyrimidoindole, ciclazindol, in the rat and patas monkey. Drug Metab Dispos 1977 0.80
36 Pharmacokinetics and metabolism of the new analgesic meptazinol in rats and patas monkeys. Xenobiotica 1976 0.79
37 Effects of inducible MEK1 activation on the cytokine dependency of lymphoid cells. Leukemia 2001 0.79
38 A novel study of association between Neisseria gonorrhoeae and the human carbohydrate blood groups. Immunohematology 2007 0.78
39 Synergistic effects of pi3k/akt on abrogation of cytokine-dependency induced by oncogenic raf. Adv Enzyme Regul 2001 0.78
40 The influence of gastric emptying on plasma concentrations of the analgesic, meptazinol. Br J Pharmacol 1977 0.77
41 Synergy between Raf and BCL2 in abrogating the cytokine dependency of hematopoietic cells. Leukemia 2000 0.77
42 Oxidative stress regulates the interaction of p16 with Cdk4. Biochem Biophys Res Commun 2000 0.77
43 Monocytes express a non-neurokinin substance P receptor that is functionally coupled to MAP kinase. J Immunol 1994 0.76
44 T cell receptor assembly and expression in the absence of calnexin. Arch Biochem Biophys 2000 0.76
45 Chicken serum inhibits lectin-induced proliferation of autologous splenic mononuclear cells. Proc Soc Exp Biol Med 1987 0.76
46 The pharmacokinetics of indoramin and 6-hydroxyindoramin in poor and extensive hydroxylators of debrisoquine. Eur J Clin Pharmacol 1987 0.76
47 Microfilament assembly is required for anti-IgM dependent MAPK and p90rsk activation in human B lymphocytes. Biochem Biophys Res Commun 1995 0.75
48 Routes of meptazinol conjugation in the neonate. Br J Clin Pharmacol 1982 0.75
49 Pharmacodynamic correlates of modified absorption: studies with lormetazepam. Br J Clin Pharmacol 1984 0.75
50 Studies on the absorption and disposition of meptazinol following rectal administration. Br J Clin Pharmacol 1977 0.75
51 The biotransformation of ciclazindol in man. Br J Clin Pharmacol 1979 0.75
52 Autocrine stimulation of B lymphocytes by a platelet-activating factor receptor agonist, 1-palmitoyl-2-acetyl-sn-glycero-3-phosphocholine. J Immunol 1994 0.75
53 Some studies on the metabolism of BDH 7538 in animals and man with particular reference to its anti-inflammatory properties. Br J Clin Pharmacol 1976 0.75
54 A rapid, hygienic method for the preparation of fecal samples for liquid scintillation counting. Anal Biochem 1978 0.75
55 Preliminary studies on the fate of 14C-fentiazac in man. Xenobiotica 1984 0.75
56 Metabolism of 4-benzamido-1-[4-(indol-3-yl)-4-oxobutyl]piperidine in rats and monkeys. Xenobiotica 1981 0.75
57 Pharmacokinetic interaction between indoramin and ethanol. Hum Toxicol 1989 0.75
58 Ciprofloxacin resistant Neisseria gonorrhoea in New Zealand. N Z Med J 1996 0.75
59 The systemic availability of meptazinol in man after oral and rectal doses. Eur J Clin Pharmacol 1989 0.75
60 The disposition of meptazinol after single and multiple intravenous administration to pregnant and non-pregnant women. Eur J Clin Pharmacol 1989 0.75
61 Studies on the metabolism of the new anti-hypertensive agent, indoramin, in man. Eur J Clin Pharmacol 1983 0.75
62 A mixed isotope method for the study of gastric absorption of drugs. J Pharm Pharmacol 1977 0.75
63 The Drug Metabolism Discussion Group 1991. Xenobiotica 1992 0.75
64 Intra- and inter-subject variation in the pharmacokinetics of indoramin and its 6-hydroxylated metabolite. Eur J Clin Pharmacol 1988 0.75
65 Pharmacokinetics of oral indoramin in elderly and middle-aged female volunteers. Eur J Clin Pharmacol 1984 0.75
66 The pharmacokinetics of fentiazac and its metabolite, p-hydroxyfentiazac, after twice-daily oral administration to male volunteers. Xenobiotica 1984 0.75
67 Pharmacokinetics of meptazinol after parenteral administration in the elderly. Eur J Clin Pharmacol 1987 0.75
68 Pharmacokinetics and systemic availability of the antihypertensive agent indoramin and its metabolite 6-hydroxyindoramin in healthy subjects. Eur J Clin Pharmacol 1987 0.75
69 Pharmacokinetics of indoramin and its 6-hydroxylated metabolite after repeated oral dosing. Biopharm Drug Dispos 1988 0.75
70 On the relation between the analgesic activity of meptazinol and its plasma concentrations in rats, mice and monkeys. J Pharm Pharmacol 1976 0.75
71 Pharmacokinetic studies on tiquinamide, a novel inhibitor of gastric acid secretion. Br J Clin Pharmacol 1976 0.75
72 Enhanced ability of daniplestim and myelopoietin-1 to suppress apoptosis in human hematopoietic cells. Leukemia 2001 0.75
73 A soluble 61-kDa protein is associated with inhibition of lectin-induced proliferation and IL-2 synthesis. Proc Soc Exp Biol Med 1987 0.75
74 The pharmacokinetics of pirtenidine in the rat and dog. Xenobiotica 1989 0.75
75 Quantitative aspects of the urinary excretion of meptazinol and its metabolites in human volunteers. Xenobiotica 1989 0.75
76 The disposition of a novel tetrahydroquinoline, tiquinamide, in rats and patas monkeys. Eur J Drug Metab Pharmacokinet 1982 0.75
77 Studies on the biotransformation of indoramin in the patas monkey. Xenobiotica 1981 0.75
78 Butylated hydroxytoluene in sarcoma-prone dogs. Lancet 1976 0.75
79 Pharmacokinetics of meptazinol after single and multiple oral administration to elderly patients. Eur J Clin Pharmacol 1984 0.75